Formulary Committee members with a potential conflict of interest participation in committee communications and discussions authorization provision, public comment process for recommendations to the Formulary Committee development by the commissioner of human services requirement provision, and Minnesota Rare Disease Advisory Council expertise sought by the Formulary Committee requirement provision

SF 2645 modifies Minnesota's Formulary Committee, which determines which prescription drugs are covered under medical assistance programs (like Medicaid). The bill allows committee members with potential conflicts of interest to participate in communications and discussions about related drug coverage (though they must recuse from votes), requires the commissioner of human services to create a public comment process for recommendations to the committee, and mandates that the committee seek input from the Minnesota Rare Disease Advisory Council on rare disease drug coverage. These changes aim to improve transparency in decision-making and incorporate specialized expertise without altering which drugs are covered. The bill affects the committee's operations, public engagement, and use of advisory council input.